The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...

Cirrhosis is one of the leading causes of mortality from non-communicable diseases, with complications arising as liver function deteriorates. HRS and HPS represent the most severe outcomes of ...

Novartis Fabhalta meets phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy: Basel Friday, October 17, 2025, 10:00 Hrs [IST] Novartis announ ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Palopegteriparatide improved skeletal dynamics and renal ...

GFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 Fabhalta is first and only approved complement inhibitor for adults ...

Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Long-term results of a single-institutional experience. Background: A four-weekly ...

The Paradise uRDN system is a novel ultrasound-based renal denervation technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 17, 2025 /EINPresswire.com/ -- What Is The Estimated Industry Size Of Veterinary Renal Disease Market? In recent times, the market size for veterinary ...